Low Growth Hormone Symptoms: Labs, Diagnosis, and Next Steps

What Growth Hormone Does in Adults

Growth hormone (GH) is not only for children. In adults, GH secreted by the anterior pituitary regulates body composition, lipid metabolism, bone turnover, cardiac function, and subjective well-being through direct receptor binding and hepatic production of IGF-1 [1]. GH pulses peak during slow-wave sleep and decline naturally with age at roughly 14% per decade after age 30.

The distinction between normal age-related GH decline (sometimes called somatopause) and true pathological deficiency matters. Normal aging reduces mean 24-hour GH secretion from approximately 600 µg/day at age 20 to roughly 200 µg/day by age 60, but IGF-1 typically remains within the age-adjusted reference range [2]. Pathological AGHD, by contrast, produces IGF-1 values below the lower limit of normal and triggers a recognizable clinical syndrome. The Endocrine Society's 2011 clinical practice guideline defines AGHD as a distinct biochemical and clinical entity requiring confirmatory dynamic testing before treatment [1].

Recognizing where you fall on that spectrum is the first step. The sections below walk through the symptoms that should prompt evaluation, the labs your clinician will order, what the results mean, and the treatment options available once a diagnosis is confirmed.

Symptoms That Should Prompt a GH Evaluation

The clinical picture of AGHD is nonspecific when each symptom is viewed in isolation, but the pattern is distinctive. Increased central adiposity, reduced lean body mass, fatigue, low exercise capacity, and impaired psychological well-being cluster together in a way that separates AGHD from garden-variety deconditioning [1].

Body composition shifts are often the most visible change. A 2009 meta-analysis of 16 controlled trials found that untreated AGHD patients carried an average of 7.5 kg more fat mass than matched controls, with preferential accumulation in visceral depots [3]. Lean mass simultaneously decreases. Patients frequently describe difficulty maintaining muscle despite adequate protein intake and resistance training.

Bone density declines in parallel. The GH Research Society consensus statement notes that AGHD patients show osteopenia or osteoporosis at rates two to three times higher than age-matched populations, with fracture risk elevated accordingly [4]. Fatigue is subjective but measurable: validated instruments like the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) consistently show scores 4 to 6 points worse in untreated AGHD compared to population norms [5].

Cardiovascular risk markers also shift. LDL cholesterol rises, HDL cholesterol falls, and carotid intima-media thickness increases. A 2007 study in the Journal of Clinical Endocrinology & Metabolism showed that AGHD patients had a 1.9-fold higher cardiovascular mortality rate than predicted [6]. These are not cosmetic complaints. They represent measurable, treatable pathology.

Common Causes of Low Growth Hormone in Adults

Pituitary adenomas and their treatments account for the majority of AGHD cases. Surgery and radiation for sellar and parasellar tumors damage somatotroph cells or the hypothalamic-pituitary stalk, and GH is typically the first anterior pituitary hormone lost after such insults [1].

Traumatic brain injury (TBI) is an increasingly recognized cause. A 2005 prospective study by Agha et al. found GH deficiency in 10.7% of TBI survivors at 12 months post-injury [7]. Subarachnoid hemorrhage produces similar rates. These patients are frequently missed because endocrine screening after neurotrauma remains inconsistent.

Other causes include:

• Childhood-onset GHD persisting into adulthood (requires retesting after final height is reached, as roughly 30% of childhood cases resolve [1])
• Cranial irradiation for leukemia, brain tumors, or nasopharyngeal carcinoma (GHD may appear 2 to 5 years post-radiation at doses above 30 Gy [8])
• Infiltrative diseases such as sarcoidosis, hemochromatosis, and Langerhans cell histiocytosis
• Sheehan syndrome (postpartum pituitary necrosis)
• Idiopathic AGHD, diagnosed when no structural cause is identified but biochemical criteria are met

"Clinicians should have a high index of suspicion for GH deficiency in any patient with a history of pituitary or hypothalamic disease, head trauma, cranial irradiation, or known deficiency of other pituitary hormones," the Endocrine Society guideline states [1].

The Screening Lab: Serum IGF-1

IGF-1 is the first-line screening test. It reflects integrated 24-hour GH secretion because the liver produces IGF-1 in proportion to GH stimulation, and its half-life of 12 to 15 hours smooths out the pulsatile variability inherent in random GH levels [1]. A single random GH measurement is unreliable and should not be used to diagnose or exclude AGHD.

Results must be interpreted against age- and sex-specific reference ranges. An IGF-1 of 90 ng/mL might be normal in a 70-year-old woman but clearly low in a 30-year-old man. Most reference laboratories provide percentile rankings alongside absolute values.

A low IGF-1 in a patient with a compatible clinical picture and a known risk factor (pituitary surgery, radiation, TBI) is strongly suggestive. The Endocrine Society guideline notes that an IGF-1 below the lower limit of normal, combined with deficiency of three or more other pituitary hormones, has a positive predictive value exceeding 95% for severe GHD, potentially obviating the need for stimulation testing [1].

A normal IGF-1 does not exclude the diagnosis. Approximately 35% of patients with confirmed GHD on stimulation testing have an IGF-1 within the normal range [9]. This is why dynamic testing remains necessary in most cases.

Nutritional status, hepatic function, estrogen use, and thyroid status all affect IGF-1 levels. Oral estrogen therapy lowers IGF-1 by increasing hepatic first-pass extraction, and untreated hypothyroidism suppresses GH secretion. These confounders must be addressed before interpreting results.

Confirmatory Testing: GH Stimulation Tests

The insulin tolerance test (ITT) has been the gold-standard provocative test for AGHD since the 1960s. It requires supervised intravenous insulin injection (0.1 to 0.15 IU/kg) to induce symptomatic hypoglycemia (blood glucose <40 mg/dL or <2.2 mmol/L), followed by serial GH measurements [1]. A peak GH response below 3 µg/L on the ITT is diagnostic for severe GHD in the United States, while European guidelines use a cutoff of 5 µg/L [4].

The ITT has real limitations. It is contraindicated in patients with seizure disorders, coronary artery disease, or age above 65 due to hypoglycemia risk. It requires an experienced endocrine nurse to administer and monitor, and not every practice has the infrastructure.

Dr. Beverly M.K. Biller, a neuroendocrinologist at Massachusetts General Hospital and co-author of the Endocrine Society guideline, has noted: "The ITT remains the reference standard, but the field has needed a practical, validated alternative for patients in whom hypoglycemia is unsafe or testing infrastructure is limited" [10].

Macimorelin (Macrilen) fills that gap. Approved by the FDA in December 2017, it is an oral ghrelin receptor agonist that stimulates GH release [11]. The patient drinks a reconstituted solution, and GH levels are drawn at 30, 45, 60, and 90 minutes. A peak GH below 2.8 µg/L confirms GHD. In the key validation study (N=157), macimorelin showed 87% sensitivity and 96% specificity against the ITT as the reference, with a negative predictive value of 93% [12].

The glucagon stimulation test (GST) is a secondary alternative when neither the ITT nor macimorelin is available. Glucagon 1 mg is injected intramuscularly, with GH samples drawn over 3 to 4 hours. A peak GH below 3 µg/L is diagnostic. Nausea is common, and the test is less well-validated in obese patients, where false-positive rates increase because adiposity blunts GH responses independent of true deficiency [1].

GHRH-arginine testing, once widely used in Europe, became unavailable in the United States after the discontinuation of GHRH (Geref) in 2008. It remains an option in countries where the reagent is still manufactured.

Interpreting Your Results: What the Numbers Mean

A practical framework for reading your labs:

| Scenario | IGF-1 | Stim Test Peak GH | Interpretation | |---|---|---|---| | Clear deficiency | Low for age | <3 µg/L (ITT) or <2.8 µg/L (macimorelin) | Severe GHD confirmed | | Probable deficiency | Low-normal | <3 µg/L (ITT) | Severe GHD confirmed (IGF-1 alone was misleading) | | Partial deficiency | Low for age | 3 to 5 µg/L (ITT) | May qualify for treatment depending on symptoms and guideline used | | Normal | Normal for age | >5 µg/L | GHD excluded; investigate other causes of symptoms |

The "partial deficiency" category generates clinical debate. The U.S. Endocrine Society uses a strict 3 µg/L cutoff, while the European Society of Endocrinology recognizes a 3 to 5 µg/L gray zone where clinical judgment and symptom burden guide the treatment decision [4]. BMI also matters: obese patients (BMI >30) need lower GH cutoffs because adiposity suppresses peak GH responses, and some experts advocate BMI-adjusted thresholds to reduce false positives [13].

If your IGF-1 is low and you have deficiencies in three or more other pituitary axes (thyroid, cortisol, gonadal hormones), most endocrinologists will diagnose severe GHD without a stimulation test. The pretest probability is simply too high to justify the cost and discomfort [1].

Treatment: Recombinant Human Growth Hormone

Once AGHD is confirmed, treatment with recombinant human GH (rhGH, somatropin) is the standard of care. Multiple branded formulations are FDA-approved for AGHD, including Norditropin, Genotropin, Humatrope, Saizen, and Omnitrope [14].

Starting doses are weight-based or fixed-low, depending on clinical context. The Endocrine Society recommends initiating at 0.1 to 0.2 mg/day for younger men, 0.2 to 0.3 mg/day for younger women (women require higher doses due to estrogen-mediated hepatic GH resistance), and 0.1 mg/day for patients over 60 [1]. Dose titration occurs every 1 to 2 months based on IGF-1 levels, targeting the mid-to-upper portion of the age-adjusted normal range.

A long-acting weekly formulation, somapacitan (Sogroya), received FDA approval in 2020 for AGHD at a starting dose of 1.5 mg subcutaneously once weekly [15]. This has improved adherence in patients who find daily injections burdensome. Lonapegsomatropin (Skytrofa), approved for pediatric GHD, is being studied in adult populations as well.

Results are measurable. The KIMS database (Pfizer International Metabolic Database), one of the largest AGHD registries, reported that after 12 months of rhGH replacement, patients showed a mean reduction in fat mass of 2.4 kg, an increase in lean body mass of 2.6 kg, and a 3.8-point improvement in QoL-AGHDA score (N=2,589) [16]. LDL cholesterol decreased by an average of 11%, and bone mineral density at the lumbar spine increased by 1.8% per year over the first 3 years [16].

Side effects are dose-dependent and usually manageable. Joint pain, peripheral edema, carpal tunnel symptoms, and paresthesias occur in 10 to 20% of patients during titration and typically resolve with dose reduction [1]. Glucose metabolism requires monitoring: rhGH increases insulin resistance, and fasting glucose or HbA1c should be checked at baseline and every 6 to 12 months, particularly in patients with pre-existing diabetes or metabolic syndrome.

Monitoring and Long-Term Follow-Up

After dose stabilization, IGF-1 is checked every 6 to 12 months. The target remains in the upper half of the age-adjusted normal range without exceeding the upper limit, as supraphysiologic IGF-1 levels have been associated with increased cancer risk in epidemiologic studies, though the clinical significance of this association during GH replacement remains debated [17].

Body composition assessment via DXA scan at baseline and every 1 to 2 years provides objective tracking of lean mass and fat mass changes. Lipid panels and bone density (DXA of the spine and hip) should be monitored at intervals appropriate to the patient's cardiovascular and skeletal risk profile.

MRI of the pituitary is recommended at baseline if not recently performed, and periodically thereafter in patients with structural pituitary disease. There is no evidence that physiologic GH replacement increases the recurrence risk of previously treated pituitary adenomas [1]. A 2012 meta-analysis of 15 studies found no significant increase in tumor regrowth among GH-treated patients compared to untreated controls [18].

Patients should also be monitored for the development or progression of other pituitary hormone deficiencies. GH replacement can unmask previously compensated cortisol deficiency (by increasing cortisol metabolism via 11β-HSD1) or worsen central hypothyroidism, requiring dose adjustments to hydrocortisone or levothyroxine [1].

When to Seek Evaluation

Do not wait for a textbook presentation. If you have a known pituitary condition, a history of brain radiation, TBI, or unexplained clustering of increased abdominal fat, declining exercise capacity, low bone density, and persistent fatigue, ask your physician for an IGF-1 level. If the result is low or borderline, a referral to an endocrinologist for stimulation testing is the next step. Early diagnosis and treatment prevent the compounding metabolic and skeletal consequences that accumulate over years of untreated deficiency. The starting dose of somatropin is small, the titration is individualized, and the objective response (body composition, lipid profile, bone density, QoL score) is tracked at every visit.